Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,346 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo intravenous Clear all
Active, not recruiting Phase 3 Interventional

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma
Interventions
Cemiplimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
40
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

NCT02175225
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Deferoxamine Mesylate, Placebo (for Deferoxamine Mesylate)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 6, 2026, 4:04 PM EDT
Active, not recruiting Phase 2 Interventional

Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement

NCT06052176
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Albumin Infusion
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of External Vibration for Pain Relief During Intravenous Access in Adult Patients

NCT03619135
View directory record Official record
Conditions
Pain Management, Anxiety
Interventions
Buzzy, Placebo
Device · Other
Lead sponsor
Kyle Stein
Other
Eligibility
18 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

I.V. Selonabant in Healthy Adult Subjects

NCT07211607
View directory record Official record
Conditions
Healthy Volunteers
Interventions
selonabant, placebo
Drug
Lead sponsor
Anebulo Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT05027269
View directory record Official record
Conditions
DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions
AOC 1001, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).

NCT04912869
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Crovalimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair

NCT01500109
View directory record Official record
Conditions
Cleft Palate
Interventions
Oral acetaminophen, Ofirmev®, Opioid only
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
5 Months to 5 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury

NCT01851083
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
autologous bone marrow mononuclear cells, Placebo Infusion
Biological · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
5 Years to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Phoenix, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2

NCT00001812
View directory record Official record
Conditions
Candidiasis, Oral, Gastrointestinal Diseases, Stomatitis
Interventions
Nystatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 4 Interventional Results available

PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement

NCT02244619
View directory record Official record
Conditions
Post-op Pain
Interventions
Oral acetaminophen, IV acetaminophen
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 6, 2026, 4:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

NCT07445971
View directory record Official record
Conditions
COVID -19, COVID-19 (Prevention)
Interventions
MDX2301, Normal Saline
Biological
Lead sponsor
ModeX Therapeutics, An OPKO Health Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 6, 2026, 4:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease

NCT01917721
View directory record Official record
Conditions
Kawasaki Disease, Coronary Aneurysm
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Hawaii Pacific Health
Other
Eligibility
1 Month to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00401843
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Siltuximab, Bortezomib, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
11
States / cities
Greenbrae, California • Los Angeles, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

NCT00538434
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years to 18 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

NCT00604214
View directory record Official record
Conditions
Sepsis
Interventions
Drotrecogin alfa (activated), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
23
States / cities
Birmingham, Alabama • Loma Linda, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AB103 Peptide Antagonist in Healthy Volunteers

NCT01166984
View directory record Official record
Conditions
Healthy Volunteer Safety Study
Interventions
AB103, Placebo
Drug
Lead sponsor
Atox Bio Ltd
Industry
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

The Effect of Thiamine vs. Placebo on VO2 in Critical Illness

NCT01985685
View directory record Official record
Conditions
Critically Ill, Respiratory Failure
Interventions
Thiamine
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

NCT04320615
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
Tocilizumab (TCZ), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
23
States / cities
La Jolla, California • La Mesa, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

NCT00080678
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
Docetaxel, Imatinib Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 6, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

NCT03172208
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Caplacizumab Dose 1 iv (single-dose), Caplacizumab Dose 2 iv (single-dose), Caplacizumab Dose 2 sc (single-dose), Caplacizumab Dose 2 sc (multiple-dose), Placebo iv (single-dose), Placebo sc (single-dose), Placebo sc (multiple-dose)
Biological · Other
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 6, 2026, 4:04 PM EDT